Axon Enterprise (NASDAQ:AXON) Stock Rating Lowered by Craig Hallum

Axon Enterprise (NASDAQ:AXON) was downgraded by stock analysts at Craig Hallum from a “buy” rating to a “hold” rating in a report released on Friday, MarketBeat Ratings reports. They presently have a $390.00 price target on the biotechnology company’s stock. Craig Hallum‘s price target indicates a potential upside of 24.60% from the company’s current price.

Several other brokerages have also recently commented on AXON. Piper Sandler reduced their target price on Axon Enterprise from $732.00 to $561.00 and set an “overweight” rating for the company in a research report on Tuesday, October 20th. Royal Bank Of Canada reissued an “outperform” rating on shares of Axon Enterprise in a report on Tuesday, July 21st. Zacks Research cut shares of Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 3rd. Morgan Stanley raised their price objective on shares of Axon Enterprise from $600.00 to $640.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Finally, Barclays raised their price objective on shares of Axon Enterprise from $523.00 to $688.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Thirteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $631.35.

Axon Enterprise Price Performance

Shares of AXON stock opened at $313.00 on Friday. Axon Enterprise has a 12 month low of $307.00 and a 12 month high of $665.07. The company has a market capitalization of $25.43 billion, a P/E ratio of 100.32, a P/E/G ratio of 5.95 and a beta of 1.48. The stock has a 50 day moving average of $441.53 and a two-hundred day moving average of $475.20. The company has a current ratio of 2.15, a quick ratio of 1.80 and a debt-to-equity ratio of 0.47.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.89 by ($0.17). The firm had revenue of $908.55 million for the quarter, compared to the consensus estimate of $934.33 million. Axon Enterprise had a net margin of 7.56% and a return on equity of 3.95%. The business’s revenue for the quarter was up 27.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.17 earnings per share. As a group, equities analysts expect that Axon Enterprise will post 2.10 EPS for the current year.

Insider Buying and Selling

In other Axon Enterprise news, President Joshua Isner sold 16,775 shares of the company’s stock in a transaction on Monday, August 31st. The stock was sold at an average price of $574.43, for a total value of $9,636,063.25. Following the sale, the president directly owned 296,974 shares in the company, valued at $170,590,774.82. This represents a 5.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jeffrey Kunins sold 9,605 shares of the company’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $626.70, for a total value of $6,019,453.50. Following the completion of the sale, the insider owned 97,761 shares in the company, valued at $61,266,818.70. This trade represents a 8.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 37,397 shares of company stock worth $21,234,034 in the last quarter. Corporate insiders own 4.20% of the company’s stock.

Hedge Funds Weigh In On Axon Enterprise

A number of institutional investors have recently modified their holdings of the stock. MassMutual Private Wealth & Trust FSB raised its position in Axon Enterprise by 122,993.6% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 461,601 shares of the biotechnology company’s stock worth $195,036,000 after purchasing an additional 461,226 shares during the last quarter. B. Metzler seel. Sohn & Co. AG acquired a new position in Axon Enterprise during the 2nd quarter worth $3,854,000. Arrowstreet Capital Limited Partnership acquired a new position in Axon Enterprise during the 1st quarter worth $15,067,000. Brown Lisle Cummings Inc. lifted its holdings in Axon Enterprise by 97,231.4% during the 2nd quarter. Brown Lisle Cummings Inc. now owns 34,066 shares of the biotechnology company’s stock worth $19,098,000 after buying an additional 34,031 shares in the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. boosted its position in Axon Enterprise by 40.7% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 15,083 shares of the biotechnology company’s stock valued at $6,406,000 after buying an additional 4,360 shares during the last quarter. 79.08% of the stock is owned by institutional investors.

Trending Headlines about Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q3 revenue reached a record $909 million, up 28% year over year, while software and services revenue rose 43%. Axon also reported AI annual recurring revenue above $100 million, signaling continued demand for its software and AI offerings. Axon Q3 results
• Neutral Sentiment: Axon committed an additional $1.2 billion to drone maker Skydio, bringing its stake to 37% and making it Skydio’s exclusive public-safety distributor in the U.S. and Canada. The move could expand Axon’s Drone as First Responder business, but its scale also raises investment and execution risks. Reuters: Axon invests in Skydio
• Negative Sentiment: Q3 adjusted earnings of $1.72 per share and revenue of $908.55 million fell short of analyst expectations. Axon’s 2026 revenue forecast was reduced to $3.6 billion from a consensus of about $3.7 billion; its Q4 revenue guidance also came in below estimates. The company cited delays in federal counter-drone projects, while margin pressure added to concerns. Zacks: Q3 miss and outlook
• Negative Sentiment: Several analysts lowered price targets after the results, and Craig Hallum downgraded AXON from Buy to Hold, adding to pressure on investor sentiment. Benzinga: analyst forecast changes
• Negative Sentiment: A class-action lawsuit over Axon’s license-plate surveillance practices is a potential additional legal and reputational overhang. Class-action announcement

Axon Enterprise Company Profile

Axon Enterprise develops technology and services for public safety agencies. Its products include TASER conducted-energy weapons, body-worn and in-car cameras, and related hardware designed to support law enforcement and other safety professionals.

The company also provides cloud-based software for managing digital evidence, records and operational workflows. Its Axon Evidence platform helps agencies store, organize and share video and other evidence, while its broader software offerings include tools for dispatch and records management.

Founded in 1993 as TASER International, the company adopted the name Axon Enterprise in 2017 as it expanded beyond conducted-energy weapons into connected devices and software.